- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases
April 29th 2025, 7:45pm
Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.
Addition of Relatlimab/Nivolumab to Azacitidine/Venetoclax Shows Safety, Early Efficacy in Adverse-Risk Frontline AML
April 29th 2025, 7:07pm
Although the combination of azacitidine alone plus relatlimab/nivolumab was deemed safe, it had limited efficacy in patients with relapsed/refractory AML.
Maintenance Fruquintinib Plus Capecitabine Is Active, Tolerable in RAS/BRAF Wild-Type mCRC
April 29th 2025, 7:00pm
Fruquintinib plus capecitabine demonstrated preliminary efficacy and safety as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer.
Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer
April 29th 2025, 6:00pm
Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.
Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies
April 29th 2025, 5:32pm
American Urological Association Annual Meeting
Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.
Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC
April 29th 2025, 5:25pm
American Urological Association Annual Meeting
Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.
Subgroup Data From ARANOTE Highlight rPFS Benefit of Darolutamide Plus ADT in Black Patients With mHSPC
April 29th 2025, 5:11pm
American Urological Association Annual Meeting
Darolutamide plus ADT improved rPFS in Black patients with metastatic hormone-sensitive prostate cancer treated in ARANOTE.
AU-007 Demonstrates Safety and Efficacy in Heavily Pretreated Solid Tumors
April 29th 2025, 4:57pm
Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with antitumor evidence.
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
April 29th 2025, 1:01am
Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.
Early ctDNA Clearance Is Associated With Response to Daraxonrasib in RAS-Mutant NSCLC
April 28th 2025, 11:37pm
Early complete clearance of ctDNA was linked with clinical responses to daraxonrasib in RAS-mutant advanced non–small cell lung cancer.
Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC
April 28th 2025, 10:00pm
S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.
Retrospective Analysis Explores Cabozantinib/Nivolumab vs Lenvatinib/Pembrolizumab in Frontline Advanced RCC
April 28th 2025, 9:14pm
American Urological Association Annual Meeting
A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC.
Dr Tang on Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC
April 28th 2025, 9:05pm
Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.
Tiragolumab Plus Atezolizumab Fails to Meet Survival End Points in Previously-Untreated, PD-L1–High NSCLC
April 28th 2025, 8:23pm
First-line tiragolumab plus atezolizumab did not improve PFS and OS vs atezolizumab alone in PD-L1–high, unresectable or metastatic NSCLC.
Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer
April 28th 2025, 8:20pm
Bria-IMT plus checkpoint inhibition showed a manageable safety profile and activity in metastatic breast cancer.
Leuprolide Acetate With Enzalutamide or Placebo Is Associated With Full Testosterone Recovery in Prostate Cancer
April 28th 2025, 6:55pm
American Urological Association Annual Meeting
The majority of patients with prostate cancer treated with an enzalutamide or leuprolide acetate regimen recovered their testosterone levels.
Dr Trinh on Outcomes for Darolutamide Plus ADT in Black Patients With mHSPC
April 28th 2025, 6:40pm
American Urological Association Annual Meeting
Quoc-Dien Trinh, MD, MBA, discusses outcomes for darolutamide plus ADT in Black patients with metastatic hormone-sensitive prostate cancer.
Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer
April 28th 2025, 6:26pm
American Urological Association Annual Meeting
Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.
Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC
April 28th 2025, 5:26pm
Treatment with 6.5 mg/kg of tegavivint was associated with primarily grade 1/2 TRAEs in patients with advanced hepatocellular carcinoma.
TMPRSS2-ERG Shows Distinct Molecular Landscape in TALAPRO-2 Population With mCRPC
April 28th 2025, 5:20pm
Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.